28th Annual Prostate Cancer Foundation Scientific Retreat

October 28 - 29, 2021
November 4 - 5, 2021
AGENDA

Thursday, October 28, 2021
*All times in U.S. PDT

VIRTUAL POSTER SESSION
Starting on Thursday October 28, 2021, 12:01 AM U.S. PDT

GENERAL SESSIONS

Welcome & Opening Remarks
7:00 AM - 7:04 AM
Howard Soule, PhD
Prostate Cancer Foundation

Session 1: Dr. Andrew Hruszkewycz Memorial Session on Measuring and Targeting Lineage Plasticity to Prevent Lethal Prostate Cancer
7:04 AM - 8:30 AM
Moderator: Andrew Armstrong, MD, ScM
Duke University

A Tale of Two Evasions: Lineage Plasticity and Tumor Heterogeneity
Ping Mu, PhD
UT Southwestern Medical Center at Dallas

Measuring CRPC Cellular Heterogeneity at the Single Cell Level to Inform Treatment Strategies
Eliezer Van Allen, MD, PhD
Harvard: Dana-Farber Cancer Institute

Measuring Lineage Plasticity and Heterogeneity in mCRPC with Liquid Biopsies to Inform Treatment
Andrew Armstrong, MD, ScM
Duke University
Targeting Transformed Neuroendocrine Cells to Overcome Treatment Resistance  
Amina Zoubeidi, PhD  
Vancouver Prostate Centre, Canada  

Followed by Live Session Discussion  

8:30 AM - 8:45 AM  
BREAK, Please Return to the Virtual Lobby to Join the Next Session  

Session 2: Therapeutic Degraders as a New Class of Prostate Cancer Treatments  
8:45 AM - 9:25 AM  

Moderator: Howard Soule, PhD  
Prostate Cancer Foundation  

Targeting Enhancer Addiction in Prostate Cancer by Impeding Chromatin Accessibility  
Arul M. Chinnaiyan, MD, PhD  
University of Michigan, Michigan Center for Translational Pathology  

Clinical Development of ARV-110, a Novel AR Degrader, in Prostate Cancer  
Debbie Chirnomas, MD, MPH  
Arvinas, Inc.  

Followed by Live Session Discussion  

9:25 AM - 9:40 AM  
BREAK, Please Return to the Virtual Lobby to Join the Next Session  

Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment  
9:40 AM - 12:00 PM  

Moderator: Michael Hofman, MBBS  
Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia  

LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer  
Michael Hofman, MBBS  
Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia
Thursday, October 28, 2021

**Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC**
Shahneen Sandhu, MBBS
Peter MacCallum Cancer Centre, Australia

**Targeting Micro-Metastatic Disease with Auger or Alpha Emitters**
Ana Kiess, MD, PhD
Johns Hopkins University

**The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy**
Cristina Müller, PhD, PD
Paul Scherrer Institute, Switzerland

**aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans**
Aseem Anand, PhD
Imaging-Oncology Biomarker, EXINI Diagnostics AB. Sweden (a wholly owned subsidiary of Lantheus Holdings)

**Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer?**
Andy Simmons, PhD
Clovis Oncology

**Insights & Future Predictions from 25 Years of PSMA Research**
Neil Bander, MD
Weill Cornell Medical College

**Followed by Live Session Discussion**

12:00 PM - 12:15 PM  *BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session*

**VIRTUAL POSTER SESSION 1**
12:15 PM - 1:45 PM

Come to the Poster Hall for Live Discussions with Virtual Poster Session 1 Presenters

**PCF DOCTOR-PATIENT SUMMIT: Live from the Scientific Retreat**
1:00 PM - 3:00 PM

END DAY
**Session 4: Prostate Cancer Disparities**  
**7:00 AM - 8:40 AM**

**Moderator:** Kosj Yamoah, MD, PhD  
Moffitt Cancer Center

*Overview on Prostate Cancer Disparities in African Americans: Lessons from the VA Health System and VANDAAM Study*

Kosj Yamoah, MD, PhD  
Moffitt Cancer Center

Isla Garraway, MD, PhD  
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

*Epidemiologic Aspects of Prostate Cancer in Black Men and Men of African Ancestry*

Lorelei Mucci, ScD  
Harvard T.H. Chan School of Public Health

*Disparities in Metastatic Prostate Cancer and Opportunities to Exploit Biology to Improve Outcomes*

Franklin Huang MD, PhD  
University of California, San Francisco

*Evidence and Solutions in Access with Equitable Health Care as a Contributor to Prostate Cancer Disparities*

Brandon Mahal, MD  
University of Miami

*The Importance of Clinical Trial Diversity & Lessons from the COVID-19 Vaccine Trial*

Sandra Amaro, MBA  
Pfizer

Followed by Live Session Discussion

**8:40 AM - 8:55 AM**  
*BREAK, Please Return to the Virtual Lobby to Join the Next Session*
Session 5: Prostate Cancer Survivorship
8:55 AM - 10:45 AM

Moderator: Alicia Morgans, MD, MPH
Harvard: Dana-Farber Cancer Institute

Prostate Cancer Survivorship: New Programs and Strategies
Alicia Morgans, MD, MPH
Harvard: Dana-Farber Cancer Institute

Updates and Preliminary Results from the PCF-SURECaP Survivorship Working Group Initiatives: COGCaP and ARACOG
Charles J. Ryan, MD
University of Minnesota; Prostate Cancer Foundation

Sleep Dysfunction and Prostate Cancer
Stacy Loeb, MD, MSc, PhD (Hon)
New York University; Manhattan Veterans Affairs Hospital

Utilization of an “Exercise is Medicine” Approach to Optimize Treatment and Health Outcomes among Prostate Cancer Survivors
Christina Dieli-Conwright, PhD, MPH
Harvard: Dana-Farber Cancer Institute

Prostate Cancer Survivorship at the VA: Leveraging Existing Veterans' Data to Improve Cardiovascular and Bone Health
Ravi Parikh, MD, MPP
University of Pennsylvania; The Corporal Michael J. Crescenz VA Medical Center

Patient Perspective - ADT, Exercise and QoL
Joël Pointon, MPH
Patient and Advocate

Followed by Live Session Discussion

Special Lecture: ADT and CV Risk: Why Relugolix?
10:45 AM - 11:05 AM

Neal Shore, MD
Carolina Urologic Research Center
GenesisCare, US

Introduced and Moderated by Howard Soule, PhD
Prostate Cancer Foundation

Followed by Live Discussion
Friday, October 29, 2021

11:05 AM - 11:20 AM  **BREAK, Please Return to the Virtual Lobby to Join the Next Session**

**Session 6: Predicting Risk of Prostate Cancer with Polygenic Scores**
11:20 AM - 12:20 PM

**Moderator: Tyler Seibert, MD, PhD**
University of California, San Diego

*Genetic Risk Prediction for Prostate Cancer*
Christopher Haiman, ScD
University of Southern California

*Genetic Risk Stratification for Prostate Cancer: Genomics, Ancestry, and Disparities*
Tyler Seibert, MD, PhD
University of California, San Diego

*A Healthy Lifestyle in Men with a High Prostate Cancer Polygenic Risk Score*
Anna Plym, PhD
Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health

**Followed by Live Session Discussion**

12:20 PM - 12:30 PM  **BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session**

**VIRTUAL POSTER SESSION 2**
12:30 PM - 2:00 PM

Come to the Poster Hall for Live Discussions with Virtual Poster Session 2 Presenters

**END DAY**
Thursday, November 4, 2021

Session 7: Next Generation Precision Medicine
7:00 AM - 8:10 AM

Moderator: Felix Feng, MD
University of California, San Francisco

A Multi-Omic Perspective on mCRPC
Felix Feng, MD
University of California, San Francisco

Using Genomics and Histopathology to Understand Therapeutic Responses in Prostate Cancer
Joel Greshock
Janssen Oncology

Lessons from Esophageal Cancer Genomics
Rebecca Fitzgerald, PhD
University of Cambridge, United Kingdom

Followed by Live Session Discussion

8:10 AM - 8:25 AM  BREAK, Please Return to the Virtual Lobby to Join the Next Session

PCF WOMEN IN SCIENCE AWARD LECTURE: Tumor Suppressors Reimagined: Converting Understanding of RB Action into Translational Potential
8:25 AM - 9:10 AM

Karen Knudsen, MBA, PhD
American Cancer Society

Introduced and moderated by Andrea Miyahira, PhD and Howard Soule, PhD
Prostate Cancer Foundation

Followed by Live Discussion
Thursday, November 4, 2021

**KEYNOTE ADDRESS**
9:10 AM - 10:10 AM

Michael Milken
Founder and Chairman
Prostate Cancer Foundation

*Introduced by Stuart Holden, MD*
*Prostate Cancer Foundation*

10:10 AM - 10:25 AM  *BREAK, Please Return to the Virtual Lobby to Join the Next Session*

**SPECIAL LECTURE: Oncology: A Storied Past and Portentous Future**
10:25 AM - 11:00 AM

Anna Barker, PhD
Lawrence J. Ellison Institute for Transformative Medicine of the University of Southern California

*Introduced and moderated by Howard Soule, PhD*
*Prostate Cancer Foundation*

Followed by Live Discussion

**SPECIAL LECTURE**
11:00 AM - 11:40 AM

*PCF 3.0: Serving the Science, the Scientist and the Patient*
Charles J. Ryan, MD
Prostate Cancer Foundation

*Introduced and moderated by Howard Soule, PhD*
*Prostate Cancer Foundation*

Followed by Live Discussion
Thursday, November 4, 2021

Session 8: Glucocorticoid Receptor Biology in Castration Resistant Prostate Cancer  
11:40 AM -12:40 PM

Moderator: Nima Sharifi, MD  
Cleveland Clinic

Acquired Defects in Glucocorticoid Metabolism in Enzalutamide-Resistant Prostate Cancer  
Nima Sharifi, MD  
Cleveland Clinic

Targeting the Glucocorticoid Receptor Pathway in CRPC  
Suzanne D. Conzen, MD  
UT Southwestern Medical Center

Diverse Roles of the Androgen Receptor in Breast and Prostate Cancer  
Wayne Tilley, PhD  
University of Adelaide, Australia

Followed by Live Session Discussion

12:40 PM - 1:00 PM  BREAK, Please Return to the Virtual Lobby to Join the Live Poster Discussion Session

VIRTUAL POSTER SESSION 3  
1:00 PM - 2:30 PM

Come to the Poster Hall for Live Discussions with Virtual Poster Session 3 Presenters

END DAY
Friday, November 5, 2021

**Session 9: Real World Evidence and Synthetic/Virtual Control Arms**
7:00 AM - 8:00 AM

**Moderator:** Julie Lynch, PhD, RN, MBA
VINCI Precision Medicine, Salt Lake City VA & University of Utah

**Opportunities and Pitfalls of Conducting Prostate Cancer Research using Big Data in the VA**
Julie Lynch, PhD, RN, MBA
VINCI Precision Medicine, Salt Lake City VA & University of Utah

**Analysis of the VA Prostate Cancer Data: A Valuable Resource that can now be Leveraged by Everyone**
Tito Fojo, MD, PhD
Columbia University and the James J. Peters VAMC

**Using Real World Evidence to Drive Stakeholder Decisions in Oncology**
Michael Spencer, MSc
Janssen Oncology

**Followed by Live Session Discussion**

**Special Lecture: Tumor Metabolism as a Driver and Treatment Target in Prostate Cancer**
8:00 AM - 8:35 AM

**Massimo Loda, MD**
Weill Cornell Medicine

*Introduced and moderated by Howard Soule, PhD*
**Prostate Cancer Foundation**

**Followed by Live Discussion**

8:35 AM - 8:50 AM  **BREAK, Please Return to the Virtual Lobby to Join the Next Session**

**Session 10: Widening the Aperture; New Approaches for Immunotherapy in Prostate Cancer**
8:50 AM - 10:35 AM

**Moderator:** Amy Moran, PhD
Oregon Health & Science University
Friday, November 5, 2021

**A T Cell Intrinsic Role for Androgen Receptor Signaling and Immunotherapy Resistance**
Amy Moran, PhD
Oregon Health & Science University

**Checkpoint Immunotherapy in mCRPC with CDK12-Loss**
Ajjai Alva, MD
University of Michigan

**MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With mCRPC: Preliminary Results of Phase 1 Cohort Expansion**
Chet Bohac, PharmD, MD, MSc
MacroGenics, Inc.

**Targeting DLL3 with a Bi-Specific T Cell Engager: AMG 757 in De Novo and Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer**
Rahul Aggarwal, MD
University of California, San Francisco

**Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer**
Oliver Sartor, MD
Tulane University

Followed by Live Session Discussion

10:35 AM - 10:50 AM  *BREAK, Please Return to the Virtual Lobby to Join the Next Session*

**Session 11: Novel Technologies to Overcome the Suppressive Tumor Microenvironment**
10:50 AM - 12:15 PM

**Moderator: Marco Gottardis, PhD**
Janssen Research & Development, LLC

**Introduction**
Marco Gottardis, PhD
Janssen Research & Development, LLC

**Improving CAR Responses against Solid Tumors with Conditional Payload Delivery**
Gus Zeiner, PhD
Chimera Bioengineering
Friday, November 5, 2021

Combining Adenosine Pathway Inhibitors with Immunotherapy Agents in Prostate Cancer
Peter Fan, PhD
Teon Therapeutics

Mobilizing the Immune System with Bispecific Antibodies and Optimized Cytokines
John Desjarlais, PhD
Xencor

Microenvironment on Demand (MOD) – A Flexible Droplet-Microfluidic Platform to Accelerate Cell/Antibody Therapy Discoveries
Maithreyan Srinivasan, PhD
Scribe Biosciences

Followed by Live Session Discussion

Closing Remarks
12:15 PM - 12:20 PM
Howard Soule, PhD
Prostate Cancer Foundation
Andrea Miyahira, PhD
Prostate Cancer Foundation

Meeting Adjourned
Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)
Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Andrew Armstrong, MD, ScM (Duke University)
Paul Boutros, PhD (University of California, Los Angeles)
Marco Gottardis, PhD (Janssen Research & Development, LLC)
Michael Hofman, MBBS (Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia)
Alicia Morgans, MD, MPH (Harvard: Dana-Farber Cancer Institute)
Nima Sharifi, MD (Cleveland Clinic)
Kosj Yamoah, MD, PhD (Moffitt Cancer Center)
We deeply thank our Retreat supporters for providing funding for this educational initiative.